SELLAS Life Sciences Group, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $0 | $1.0M | $7.6M |
| Cost of revenue | $0 | $0 | $0 | $100,000 | $200,000 |
| Selling, general & administrative | $12.3M | $12.4M | $13.9M | $12.6M | $11.3M |
| Research and development | $16.0M | $19.1M | $24.0M | $20.3M | $15.7M |
| Operating income | -$28.3M | -$31.5M | -$37.9M | -$42.0M | -$25.3M |
| Pretax income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | -$20.9M |
| Income tax expense | $0 | $0 | $0 | $0 | -$237,000 |
| Net income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | -$20.7M |
| Balance Sheet | |||||
| Cash and equivalents | $71.8M | $13.9M | $2.5M | $17.1M | $21.4M |
| Current assets | $75.2M | $16.3M | $3.2M | $17.8M | $23.0M |
| Total assets | $78.3M | $19.4M | $6.2M | $20.9M | $26.3M |
| Current liabilities | $7.0M | $9.5M | $13.7M | $15.5M | $5.0M |
| Total liabilities | $7.5M | $10.0M | $14.2M | $16.1M | $5.9M |
| Stockholders' equity | $70.9M | $9.5M | -$8.0M | $4.9M | $20.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$28.4M | -$35.4M | -$31.4M | -$23.8M | -$26.0M |
| Stock-based compensation | $2.0M | $1.6M | $2.1M | $1.7M | $1.0M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 186.0M · Free float 98.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.